Track topics on Twitter Track topics that are important to you
We are dedicated to having a positive effect on the lives of people living with illness and disease. We have demonstrated this by bringing important new therapies from discovery to market. GelTex’s first product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the U.S. Food and Drug Administration (FDA) in October 1998 for the reduction of serum phosphorus in hemodialysis patients.
In addition, WelCholTM brand colesevelam hydrochloride was granted marketing approval by the FDA in May 2000, for the treatment of hypercholesterolemia, a condition characterized by undesirably high blood cholesterol levels.
153 Second Avenue
United States of America
Phone: 781 290 5888
Fax: 781 290 5890
FY16 Cash Flows From Operations Surpassed $22 Million in the First Quarter FY16 Diluted EPS of $0.27 Increased 35% Compared to First Quarter FY15 PITTSBURGH, Oct. 27, 2015 (GLOBE NEWSWIRE...
LOUISVILLE, Ky., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (NASDAQ:CHDN) (CDI or Company) today reported business results for the third quarter ended September 30, 2015. Re...
PITTSBURGH, Oct. 20, 2015 (GLOBE NEWSWIRE) -- II-VI Incorporated (NASDAQ:IIVI) today announced that it intends to release its fiscal 2016 first quarter results for the period ended September 30, 2015...
--Strong operational execution drives third quarter 2015 operating margin and diluted earnings per share performance --Agent productivity gains cushion cost impacts of capacity additions ...
PITTSBURGH, Oct. 27, 2015 (GLOBE NEWSWIRE) -- II-VI Incorporated (NASDAQ:IIVI), a leading provider of solutions for next generation optical networks, today announced the commercial availability of th...
CLEVELAND and WHIPPANY N.J., Nov. 19, 2015 (GLOBE NEWSWIRE) -- TransDigm Group Incorporated ("TransDigm") (NYSE:TDG) and Breeze-Eastern Corporation ("Breeze-Eastern") (NYSE MKT:BZC) today announced a...
PITTSBURGH, Pa., Nov. 9, 2015 (GLOBE NEWSWIRE) -- II-VI Incorporated (Nasdaq:IIVI) announced the results of its Annual Meeting of Shareholders held on Friday, November 6, 2015. The following propos...
LOUISVILLE, Ky., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (CDI or Company) (NASDAQ:CHDN) announced today the Company will release 2015 third-quarter business results on Wedn...
In Japan, there are 47 prefectures with differences in topography, industrial structure, population distribution and hypertension rate as well. The authors' home prefecture of Wakayama has the highest...
GelTex Pharmaceuticals, Inc. is developing non-absorbed, polymer-based pharmaceuticals that selectively bind to andeliminate target substances from the intestinal tract. In October 1998, the Company r...
We are dedicated to having a positive effect on the lives of people living with illness and disease. We have demonstrated this by bringing important new therapies from discovery to market. GelTex’s ...
We have published hundreds of GelTex Incorporated news stories on BioPortfolio along with dozens of GelTex Incorporated Clinical Trials and PubMed Articles about GelTex Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GelTex Incorporated Companies in our database. You can also find out about relevant GelTex Incorporated Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...